Eight Chinese Innovative Biopharma Companies — BeiGene Tianheng, Fosun Henlius, Hansoh Pharma, Hengrui Medicine, Akeso, Kelun-Biotech, 3SBio, and Innovent — Named to Forbes China's 2025 List of Top 50 Most Innovative Enterprises

Nov 13, 2025 22:40 CST Updated 22:40

Biokin

Pharmaceutical R&D Developer

Henlius

Innovative Biopharmaceutical Company

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Akeso

Innovative Antibody Drug Developer

Kelun-Biotech

Innovative Drug Developer

3SBIOINC

Biopharmaceutical Manufacturer

Innovent

High-end Biologics Developer

Vacancy Available, Seeking Talented Individuals
PharmTimes Recruitment【Senior BD Manager / BD Manager】
Interested young talents are invited to submit their resumes to
DrugTimes HR Department
HR@drugtimes.cn

Main Body:200Word 1 Image

Estimated reading time: 3 minutes

(Image Source: Forbes)

On November 13, 2025, Forbes released [Top 50 Innovative Companies in China by Forbes China 2025】，SelfForbes China"Innovative Enterprise"50Strong"Since the first release of the list nine years ago, thanks to the recent efforts of Chinese pharmaceutical companies,License-outStrategy: This year, the number of newly emerged innovative companies in the pharmaceutical field has reached8Home, doubled compared to last year.

Congratulations to Biokin, Shanghai Henlius Biotech, Inc., Hansoh Pharma, Hengrui Pharma, Akeso, Kelun-Biotech, 3SBIOINC, and Innovent Bio for being ranked in the Forbes China Top 50 Innovative Enterprises of 2025!

The evaluation dimensions for Forbes China's Top 50 Innovative Enterprises in 2025 include innovation capability (R&D investment and core independent intellectual property rights), corporate governance (the degree of digitalization and management level), business growth (performance of core financial indicators over the past three years), market advantages driven by innovation (market share of core products and product substitutability), and corporate social image, among others. Meanwhile, with a focus on innovation as the core, the development and organizational expansion of enterprises are assessed. This year, Forbes China has paid more attention to contributors who bring technologies that have the potential to change the world but are still far from realization into the real world, evaluating them based on the progress of technology implementation and landmark events.

References:

1. Forbes China Top 50 Innovative Enterprises 2025 (Forbes)

2. From Ren Zhengfei's "Theory of Cold" and "Huawei's Winter" to the Overseas Expansion of Chinese Pharmaceutical Companies. XtalPi, WuXi Biologics, Hengrui Pharma, and Innovent Bio Make Forbes List! ... | PharmaTimes Overseas Series

3. Talented and Extraordinary! These "Goddesses" of China's Pharmaceutical Industry Made the List of "2022 Forbes China Top 50 Women in Tech"

4. Forbes Rich List: Sun Piaoyang Family Falls Out of Top Ten, Zhong Shanshan New Richest...

5. 22 Female Pharma CEOs Made It to Forbes' 2021 List of China's 100 Most Outstanding Businesswomen!

6. Forbes Latest Global 2000: Pfizer Still Tops, Seven Chinese Pharmaceutical Companies Make the List

7. Forbes Healthcare "30 Under 30" List Announced: Meet the Achievements of These Young Talents

8. Other Public Information

Image Source: Forbes
The Golden Opportunity Has Arrived! China's Pharmaceutical Innovation Steps onto the International Stage
2025-11-10
CDER Changes Leadership, Turns Out to Be an "Old Acquaintance" of Chinese Pharmaceutical Companies
2025-11-12
RMB 2.045 Billion! Qilu Pharma Acquires AKT Inhibitor from Laekna Therapeutics
2025-11-12
【Breaking News】FDA Announces Richard Pazdur to Immediately Assume Role as CDER Director!
2025-11-12
Not Even Google Can Help! AbbVie Terminates an 11-Year-Long Collaboration
2025-11-13
$204 Million! Adicon Acquires Crown Bioscience
2025-11-13

Copyright Statement/Disclaimer
This is a compiled article.
This article is for informational exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the internet. Some materials are used under the CC0 protocol, and their copyrights belong to the respective owners. PharmaTimes makes every effort to acknowledge the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
ClickView more exciting content!